Johnson & Johnson Beat, Raised Guidance, and Still Closed Down Nearly 3%
Johnson & Johnson beat on the top and bottom line and raised full-year guidance by more than the size of the beat. The stock opened higher, then closed down 2.69%. A heart pump business generating…
Read the full articleYou might also wanna read
J&J Stock Slips Despite Earnings Beat as Company Raises Guidance Toward $100 Billion Sales Milestone Today
Johnson & Johnson's stock fell despite exceeding Q2 earnings expectations, as investor optimism had already been priced in. The company rais
Why Johnson & Johnson (JNJ) Stock Declined Despite Strong Q2 Earnings Beat
Johnson & Johnson (JNJ) shares fell 2% despite beating Q2 estimates with $2.90 EPS and $25.31B revenue, while raising full-year guidance on
J&J quarterly earnings beat Wall Street estimates on strength of medicines unit
By Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as stron
J&J quarterly earnings beat Wall Street estimates on strength of medicines unit
Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday and also increased its full-year sales and p
J&J MedTech growth slows again in Q2 as Abiomed weighs on results
Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, as weaker Abiome
The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setu
Comments
Sign in to join the conversation.
No comments yet. Be the first.